{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:17:24Z","timestamp":1790702244492,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T00:00:00Z","timestamp":1372204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Seborrheic dermatitis (SD) is normally treated with topical corticosteroids and antifungals. Oral therapies can be prescribed in severe or unresponsive cases. This review aims to assess the quantity and quality of published reports on oral therapies for SD. MEDLINE and Embase databases and the reference listings of publications were searched for any publication using oral treatment for SD. The quality of the included publications was assessed using a modified 27 item checklist by Downs and Black. Twenty\u2010one publications (randomized controlled trials, open trials and case reports) covering eight oral therapies (itraconazole, terbinafine, fluconazole, ketoconazole, pramiconazole, prednisone, isotretinoin and homeopathic mineral therapy) were identified. Most of the publications investigated oral antifungals and the quality of the evidence was generally low. The clinical efficacy outcome reported varied considerably between the studies, preventing statistical analysis and direct comparison between treatments. However, ketoconazole therapy was associated with more relapses compared with other treatments. Itraconazole dosing regimen for SD was generally 200\u00a0mg\/day for the first week of the month followed by 200\u00a0mg\/day for the first 2\u00a0days for 2\u201311\u00a0months. Terbinafine was prescribed at 250\u00a0mg\/day either as a continuous (4\u20136\u00a0weeks) or as an intermittent regimen (12\u00a0days per month) for 3\u00a0months. Fluconazole has administered daily (50\u00a0mg\/day for 2\u00a0weeks) or weekly (200\u2013300\u00a0mg) for 2\u20134\u00a0weeks. Ketoconazole dosing regimen was 200\u00a0mg daily for 4\u00a0weeks. Finally, a single 200\u00a0mg dose of pramiconazole was administered to patients. This review also highlights key areas for consideration when designing future studies.<\/jats:p>","DOI":"10.1111\/jdv.12197","type":"journal-article","created":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T15:04:26Z","timestamp":1372259066000},"page":"16-26","source":"Crossref","is-referenced-by-count":66,"title":["Systematic Review of Oral Treatments for Seborrheic Dermatitis"],"prefix":"10.1111","volume":"28","author":[{"given":"A.K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Dermatology Department of Medicine University of Toronto Toronto ON Canada"},{"name":"Mediprobe Laboratories London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Mediprobe Laboratories London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paquet","sequence":"additional","affiliation":[{"name":"Mediprobe Laboratories London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962011000600002"},{"key":"e_1_2_6_3_1","first-page":"1","article-title":"Therapeutic update on seborrheic dermatitis","volume":"15","author":"Stefanaki I","year":"2010","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04079.x"},{"key":"e_1_2_6_5_1","first-page":"14","article-title":"Seborrheic dermatitis and Malassezia species: how are they related?","volume":"2","author":"Kim GK","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3928\/00904481-20090521-01"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000076478"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10570.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1087-0024.2005.10104.x"},{"key":"e_1_2_6_10_1","first-page":"694","volume-title":"Treatment of Skin Disease","author":"Williams J","year":"2010"},{"key":"e_1_2_6_11_1","first-page":"219","volume-title":"Evidence\u2010based Dermatology","author":"Picardo M","year":"2003"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200405060-00006"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02123.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.8.1755"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.52.6.377"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1310\/sci1301-1"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3329\/jbcps.v29i4.11326","article-title":"Efficacy of oral itraconazole in the treatment of seborrheic dermatitis","volume":"29","author":"Khondker L","year":"2012","journal-title":"J Bangl Coll Phys Surg"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01090.x"},{"key":"e_1_2_6_19_1","first-page":"1","article-title":"Itraconazole: new horizons","volume":"137","author":"Caputo R","year":"2002","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.87137"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm.41.121"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm.43.189"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802140931"},{"key":"e_1_2_6_24_1","first-page":"417","article-title":"Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non\u2010comparative study","volume":"10","author":"Shemer A","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01672.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04144.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463200501800418"},{"key":"e_1_2_6_28_1","first-page":"39","article-title":"Fluconazole and its place in the treatment of seborrheic dermatitis\u2013new therapeutic possibilities","volume":"48","author":"Zisova LG","year":"2006","journal-title":"Folia Med (Plovdiv)"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200708040-00005"},{"key":"e_1_2_6_30_1","first-page":"57","article-title":"Treatment of Malassezia species associated seborrheic blepharitis with fluconazole","volume":"51","author":"Zisova LG","year":"2009","journal-title":"Folia Med (Plovdiv)"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1984.tb04514.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1984.tb06631.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000098577"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962012000300034"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000089014"},{"key":"e_1_2_6_36_1","first-page":"59","article-title":"Effective treatment of seborrheic dermatitis using a low dose, oral homeopathic medication consisting of potassium bromide, sodium bromide, nickel sulfate, and sodium chloride in a double\u2010blind, placebo\u2010controlled study","volume":"7","author":"Smith SA","year":"2002","journal-title":"Altern Med Rev"},{"key":"e_1_2_6_37_1","first-page":"98","article-title":"Seborrheic dermatitis: an update","volume":"20","author":"Bukvi\u0107 Mokos Z","year":"2012","journal-title":"Acta Dermatovenerol Croat"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.12.011"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12197","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12197","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T13:13:34Z","timestamp":1696166014000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,26]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1111\/jdv.12197"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12197","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,26]]}}}